Asian Penny Stocks To Watch In August 2026

As of August 2026, Asian markets have been navigating a landscape shaped by geopolitical developments and economic data, with investors closely watching shifts in technology stocks and regional indices. In such a climate, identifying promising investment opportunities requires careful consideration of financial health and growth potential. Penny stocks—often representing smaller or newer companies—remain relevant for those seeking affordable entry points into potentially high-growth sectors. Below, we explore several penny stocks that stand out for their financial strength and long-term promise.

Here's a peek at a few of the choices from the screener.

ImmuneOnco Biopharmaceuticals (Shanghai) (SEHK:1541)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology company focused on the research and development of immuno-oncology therapies in China and the United States, with a market cap of HK$1.58 billion.

Operations: The company generates revenue of CN¥154.29 million from its biotechnology segment.

Market Cap: HK$1.58B

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., with a market cap of HK$1.58 billion, is currently unprofitable but has reduced losses by 23.6% annually over the past five years and maintains a strong cash runway exceeding three years. The company’s short-term assets significantly surpass its liabilities, indicating financial stability. Recent developments include the initiation of Phase II/III trials for IMM0306, targeting IgG4-related disease and systemic lupus erythematosus, highlighting its innovative approach in immuno-oncology therapies. Additionally, a share repurchase program aims to enhance earnings per share, reflecting management's confidence in future prospects.

• Click here to discover the nuances of ImmuneOnco Biopharmaceuticals (Shanghai) with our detailed analytical financial health report.
• Assess ImmuneOnco Biopharmaceuticals (Shanghai)'s future earnings estimates with our detailed growth reports.

Fujian Aonong Biological Technology Group Incorporation (SHSE:603363)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Fujian Aonong Biological Technology Group Incorporation Limited operates in the feed, pig farming, food, and supply chain services sectors both in China and internationally, with a market cap of CN¥8.17 billion.

Operations: The company generates revenue primarily from its operations in China, amounting to CN¥8.90 billion.

Market Cap: CN¥8.17B

Fujian Aonong Biological Technology Group Incorporation Limited, with a market cap of CN¥8.17 billion, is currently unprofitable but has made strides in reducing losses by 14.1% annually over the past five years. Despite its high net debt to equity ratio of 49.5%, the company has decreased its overall debt significantly from previous levels and maintains a positive cash flow, ensuring a sufficient runway for more than three years if current conditions persist. However, short-term assets (CN¥3.5 billion) fall slightly short of covering immediate liabilities (CN¥3.8 billion), posing potential liquidity challenges in the near term.

• Get an in-depth perspective on Fujian Aonong Biological Technology Group Incorporation's performance by reading our balance sheet health report here.
• Gain insights into Fujian Aonong Biological Technology Group Incorporation's historical outcomes by reviewing our past performance report.

Guizhou Xinbang Pharmaceutical (SZSE:002390)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Guizhou Xinbang Pharmaceutical Co., Ltd. manufactures and sells traditional Chinese medicine and other pharmaceutical products both in China and internationally, with a market cap of CN¥5.90 billion.

Operations: There are no specific revenue segments reported for Guizhou Xinbang Pharmaceutical.

Market Cap: CN¥5.9B

Guizhou Xinbang Pharmaceutical, with a market cap of CN¥5.90 billion, demonstrates strong financial health as its short-term assets (CN¥4.9 billion) surpass both short-term (CN¥1.4 billion) and long-term liabilities (CN¥72 million). The company has more cash than debt and has significantly reduced its debt-to-equity ratio from 66.3% to 5.7% over five years, indicating prudent financial management. Despite a recent earnings growth of 52.4%, the dividend yield of 2.89% is not well covered by earnings, suggesting potential sustainability concerns in the long term for income-focused investors.

• Take a closer look at Guizhou Xinbang Pharmaceutical's potential here in our financial health report.
• Explore historical data to track Guizhou Xinbang Pharmaceutical's performance over time in our past results report.

Key Takeaways

• Click through to start exploring the rest of the 1,038 Asian Penny Stocks now.
• Contemplating Other Strategies? Trump has pledged to "unleash" American oil and gas and these 23 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com